SQZB — SQZ Biotechnologies Co Share Price
Last trade - 00:00- $1.18m
- -$9.01m
- $21.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.63 | ||
| Price to Tang. Book | 0.63 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -349.27% | ||
| Return on Equity | -203.37% | ||
| Operating Margin | -603.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 12.67 | 20.11 | 21 | 27.1 | 21.48 | 0.2 | n/a | 14.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.
Directors
- Amy Schulman CHM (60)
- Armon Sharei PRE (34)
- David First CHO (57)
- Howard Bernstein CSO (64)
- Lawrence Knopf GCN (59)
- Micah Zajic OTH (40)
- Paul Bolno IND (47)
- Bernard Coulie IND (55)
- Marc Elia IND (45)
- Pushkal Garg IND (53)
- Klavs Jensen IND (68)
- Marc Schegerin IND
- Sapna Srivastava IND (50)
- Patrick Vink IND (58)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- March 22nd, 2013
- Public Since
- October 30th, 2020
- No. of Shareholders
- 54
- No. of Employees
- 53
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 29,491,125
- Address
- 200 Arsenal Yards Blvd, Suite 210, WATERTOWN, 02472
- Web
- https://sqzbiotech.com/
- Phone
- +1 6177588672
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for SQZB
Similar to SQZB
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 23:24 UTC, shares in SQZ Biotechnologies Co are trading at $0.04. This share price information is delayed by 15 minutes.
Shares in SQZ Biotechnologies Co last closed at $0.04 and the price had moved by -13.98% over the past 365 days. In terms of relative price strength the SQZ Biotechnologies Co share price has underperformed the S&P500 Index by -19.63% over the past year.
The overall consensus recommendation for SQZ Biotechnologies Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSQZ Biotechnologies Co does not currently pay a dividend.
SQZ Biotechnologies Co does not currently pay a dividend.
SQZ Biotechnologies Co does not currently pay a dividend.
To buy shares in SQZ Biotechnologies Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.04, shares in SQZ Biotechnologies Co had a market capitalisation of $1.18m.
Here are the trading details for SQZ Biotechnologies Co:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SQZB
Based on an overall assessment of its quality, value and momentum SQZ Biotechnologies Co is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in SQZ Biotechnologies Co is $22.00. That is 54900% above the last closing price of $0.04.
Analysts covering SQZ Biotechnologies Co currently have a consensus Earnings Per Share (EPS) forecast of -$24.25 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SQZ Biotechnologies Co. Over the past six months, its share price has outperformed the S&P500 Index by +80.03%.
As of the last closing price of $0.04, shares in SQZ Biotechnologies Co were trading +10.09% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The SQZ Biotechnologies Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
SQZ Biotechnologies Co's management team is headed by:
- Amy Schulman - CHM
- Armon Sharei - PRE
- David First - CHO
- Howard Bernstein - CSO
- Lawrence Knopf - GCN
- Micah Zajic - OTH
- Paul Bolno - IND
- Bernard Coulie - IND
- Marc Elia - IND
- Pushkal Garg - IND
- Klavs Jensen - IND
- Marc Schegerin - IND
- Sapna Srivastava - IND
- Patrick Vink - IND